These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 23433442)

  • 1. Activity of AFN-1252, a novel FabI inhibitor, against Staphylococcus aureus in an in vitro pharmacodynamic model simulating human pharmacokinetics.
    Tsuji BT; Harigaya Y; Lesse AJ; Forrest A; Ngo D
    J Chemother; 2013 Feb; 25(1):32-5. PubMed ID: 23433442
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics, pharmacodynamics and efficacy of novel FabI inhibitor AFN-1252 against MSSA and MRSA in the murine thigh infection model.
    Banevicius MA; Kaplan N; Hafkin B; Nicolau DP
    J Chemother; 2013 Feb; 25(1):26-31. PubMed ID: 23433441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro activity (MICs and rate of kill) of AFN-1252, a novel FabI inhibitor, in the presence of serum and in combination with other antibiotics.
    Kaplan N; Awrey D; Bardouniotis E; Berman J; Yethon J; Pauls HW; Hafkin B
    J Chemother; 2013 Feb; 25(1):18-25. PubMed ID: 23433440
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mode of action, in vitro activity, and in vivo efficacy of AFN-1252, a selective antistaphylococcal FabI inhibitor.
    Kaplan N; Albert M; Awrey D; Bardouniotis E; Berman J; Clarke T; Dorsey M; Hafkin B; Ramnauth J; Romanov V; Schmid MB; Thalakada R; Yethon J; Pauls HW
    Antimicrob Agents Chemother; 2012 Nov; 56(11):5865-74. PubMed ID: 22948878
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AFN-1252, a FabI inhibitor, demonstrates a Staphylococcus-specific spectrum of activity.
    Karlowsky JA; Kaplan N; Hafkin B; Hoban DJ; Zhanel GG
    Antimicrob Agents Chemother; 2009 Aug; 53(8):3544-8. PubMed ID: 19487444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resistance to AFN-1252 arises from missense mutations in Staphylococcus aureus enoyl-acyl carrier protein reductase (FabI).
    Yao J; Maxwell JB; Rock CO
    J Biol Chem; 2013 Dec; 288(51):36261-71. PubMed ID: 24189061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Perturbation of Staphylococcus aureus gene expression by the enoyl-acyl carrier protein reductase inhibitor AFN-1252.
    Parsons JB; Kukula M; Jackson P; Pulse M; Simecka JW; Valtierra D; Weiss WJ; Kaplan N; Rock CO
    Antimicrob Agents Chemother; 2013 May; 57(5):2182-90. PubMed ID: 23459481
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacodynamic activity of ceftobiprole compared with vancomycin versus methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA) using an in vitro model.
    Zhanel GG; Voth D; Nichol K; Karlowsky JA; Noreddin AM; Hoban DJ
    J Antimicrob Chemother; 2009 Aug; 64(2):364-9. PubMed ID: 19454524
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A FASII Inhibitor Prevents Staphylococcal Evasion of Daptomycin by Inhibiting Phospholipid Decoy Production.
    Pee CJE; Pader V; Ledger EVK; Edwards AM
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30718253
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bone and Joint Tissue Penetration of the
    Menetrey A; Janin A; Pullman J; Overcash JS; Haouala A; Leylavergne F; Turbe L; Wittke F; Nicolas-Métral V
    Antimicrob Agents Chemother; 2019 Mar; 63(3):. PubMed ID: 30559136
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of AFN-1252, the First Staphylococcus-Specific Antibacterial Agent, in the Treatment of Acute Bacterial Skin and Skin Structure Infections, Including Those in Patients with Significant Comorbidities.
    Hafkin B; Kaplan N; Murphy B
    Antimicrob Agents Chemother; 2015 Dec; 60(3):1695-701. PubMed ID: 26711777
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro activity of API-1252, a novel FabI inhibitor, against clinical isolates of Staphylococcus aureus and Staphylococcus epidermidis.
    Karlowsky JA; Laing NM; Baudry T; Kaplan N; Vaughan D; Hoban DJ; Zhanel GG
    Antimicrob Agents Chemother; 2007 Apr; 51(4):1580-1. PubMed ID: 17220418
    [No Abstract]   [Full Text] [Related]  

  • 13. Activity of Debio1452, a FabI inhibitor with potent activity against Staphylococcus aureus and coagulase-negative Staphylococcus spp., including multidrug-resistant strains.
    Flamm RK; Rhomberg PR; Kaplan N; Jones RN; Farrell DJ
    Antimicrob Agents Chemother; 2015 May; 59(5):2583-7. PubMed ID: 25691627
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacodynamics of ceftaroline against Staphylococcus aureus studied in an in vitro pharmacokinetic model of infection.
    MacGowan AP; Noel AR; Tomaselli S; Bowker KE
    Antimicrob Agents Chemother; 2013 Jun; 57(6):2451-6. PubMed ID: 23459495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. AFN-1252 is a potent inhibitor of enoyl-ACP reductase from Burkholderia pseudomallei--Crystal structure, mode of action, and biological activity.
    Rao KN; Lakshminarasimhan A; Joseph S; Lekshmi SU; Lau MS; Takhi M; Sreenivas K; Nathan S; Yusof R; Abd Rahman N; Ramachandra M; Antony T; Subramanya H
    Protein Sci; 2015 May; 24(5):832-40. PubMed ID: 25644789
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The MUT056399 inhibitor of FabI is a new antistaphylococcal compound.
    Escaich S; Prouvensier L; Saccomani M; Durant L; Oxoby M; Gerusz V; Moreau F; Vongsouthi V; Maher K; Morrissey I; Soulama-Mouze C
    Antimicrob Agents Chemother; 2011 Oct; 55(10):4692-7. PubMed ID: 21825292
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AFN-1252 in vitro absorption studies and pharmacokinetics following microdosing in healthy subjects.
    Kaplan N; Garner C; Hafkin B
    Eur J Pharm Sci; 2013 Nov; 50(3-4):440-6. PubMed ID: 23988847
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety, tolerability and pharmacokinetics of multiple oral doses of AFN-1252 administered as immediate release (IR) tablets in healthy subjects.
    Hunt T; Kaplan N; Hafkin B
    J Chemother; 2016 Jun; 28(3):164-71. PubMed ID: 26431470
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model.
    Crandon JL; Banevicius MA; Nicolau DP
    Antimicrob Agents Chemother; 2009 Mar; 53(3):1165-9. PubMed ID: 19114676
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo pharmacodynamics of torezolid phosphate (TR-701), a new oxazolidinone antibiotic, against methicillin-susceptible and methicillin-resistant Staphylococcus aureus strains in a mouse thigh infection model.
    Louie A; Liu W; Kulawy R; Drusano GL
    Antimicrob Agents Chemother; 2011 Jul; 55(7):3453-60. PubMed ID: 21502615
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.